CN1686485A - 一种治疗冠心病心绞痛的药物组合物及其制备方法 - Google Patents
一种治疗冠心病心绞痛的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN1686485A CN1686485A CN 200510071171 CN200510071171A CN1686485A CN 1686485 A CN1686485 A CN 1686485A CN 200510071171 CN200510071171 CN 200510071171 CN 200510071171 A CN200510071171 A CN 200510071171A CN 1686485 A CN1686485 A CN 1686485A
- Authority
- CN
- China
- Prior art keywords
- rhizoma corydalis
- parts
- pharmaceutical composition
- powder
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 12
- 206010002383 Angina Pectoris Diseases 0.000 title claims description 56
- 238000002360 preparation method Methods 0.000 title claims description 15
- 239000000203 mixture Substances 0.000 title claims description 14
- 239000003814 drug Substances 0.000 claims abstract description 81
- 241000218176 Corydalis Species 0.000 claims abstract description 51
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 42
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000002775 capsule Substances 0.000 claims abstract description 13
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 51
- 238000011282 treatment Methods 0.000 claims description 48
- 241000208340 Araliaceae Species 0.000 claims description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 40
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 40
- 235000008434 ginseng Nutrition 0.000 claims description 40
- 229940079593 drug Drugs 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 239000000284 extract Substances 0.000 claims description 22
- 238000010992 reflux Methods 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 13
- 239000006187 pill Substances 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- 230000006837 decompression Effects 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000004064 recycling Methods 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 9
- 206010013786 Dry skin Diseases 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000006196 drop Substances 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 4
- 230000008569 process Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 78
- 210000004369 blood Anatomy 0.000 description 42
- 239000008280 blood Substances 0.000 description 42
- 238000012360 testing method Methods 0.000 description 40
- 208000002193 Pain Diseases 0.000 description 31
- 230000036407 pain Effects 0.000 description 28
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 22
- 239000000006 Nitroglycerin Substances 0.000 description 22
- 229960003711 glyceryl trinitrate Drugs 0.000 description 22
- 230000007812 deficiency Effects 0.000 description 21
- 210000000038 chest Anatomy 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 19
- 206010061876 Obstruction Diseases 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 16
- 230000003203 everyday effect Effects 0.000 description 14
- 208000011580 syndromic disease Diseases 0.000 description 14
- 210000002216 heart Anatomy 0.000 description 13
- 206010008479 Chest Pain Diseases 0.000 description 11
- 210000000115 thoracic cavity Anatomy 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 208000031225 myocardial ischemia Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 206010016256 fatigue Diseases 0.000 description 9
- 230000002107 myocardial effect Effects 0.000 description 9
- 210000002105 tongue Anatomy 0.000 description 9
- 230000010354 integration Effects 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 230000036284 oxygen consumption Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000002085 persistent effect Effects 0.000 description 7
- 206010021143 Hypoxia Diseases 0.000 description 6
- 206010003119 arrhythmia Diseases 0.000 description 6
- 230000006793 arrhythmia Effects 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000007954 hypoxia Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 238000009534 blood test Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 230000001314 paroxysmal effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 238000002562 urinalysis Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000009636 Huang Qi Substances 0.000 description 3
- 231100000111 LD50 Toxicity 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 208000006750 hematuria Diseases 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- 206010003671 Atrioventricular Block Diseases 0.000 description 2
- 206010006578 Bundle-Branch Block Diseases 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010012118 Defect conduction intraventricular Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 206010040007 Sense of oppression Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- VRSRXLJTYQVOHC-YEJXKQKISA-N corydaline Chemical compound C=1([C@H]2[C@H]3C)C=C(OC)C(OC)=CC=1CCN2CC1=C3C=CC(OC)=C1OC VRSRXLJTYQVOHC-YEJXKQKISA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 206010034754 petechiae Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 206010037833 rales Diseases 0.000 description 2
- -1 reflux Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 229940093252 sorbitrate Drugs 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010006580 Bundle branch block left Diseases 0.000 description 1
- 206010006582 Bundle branch block right Diseases 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- VRSRXLJTYQVOHC-UHFFFAOYSA-N Corydaline Natural products CC1C2C=3C=C(OC)C(OC)=CC=3CCN2CC2=C1C=CC(OC)=C2OC VRSRXLJTYQVOHC-UHFFFAOYSA-N 0.000 description 1
- 241000830532 Corydalis yanhusuo Species 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021079 Hypopnoea Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 208000008376 Pre-Excitation Syndromes Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000003734 Supraventricular Tachycardia Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000004004 anti-anginal agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 201000001715 left bundle branch hemiblock Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 208000023482 precordial pain Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 201000007916 right bundle branch block Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- NCTHNHPAQAVBEB-WGCWOXMQSA-M sodium ferulate Chemical compound [Na+].COC1=CC(\C=C\C([O-])=O)=CC=C1O NCTHNHPAQAVBEB-WGCWOXMQSA-M 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000009982 suxiao jiuxinwan Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
症状 | 轻度(+) | 中度(++) | 重度(+++) |
胸痛 | 每周发作2-3次或每日发作1-3次 | 每周数次发作,每日发作3-5次 | 每周发作多次,每日发作>5次 |
3-5分钟 | 5-10分钟 | 10-15分钟 | |
疼痛不重 | 疼痛较重 | 疼痛重,甚则影响日常生活活动 | |
胸闷气短 | 偶尔发生,缓解迅速 | 活动后发生,休息可缓解 | 稍活动即发生,缓解所需时间长 |
心悸 | 登楼或体力活动发生 | 轻微活动发生 | 静息时即有 |
倦怠懒言 | 一般体力活动发生 | 轻度体力活动发生 | 休息时即发生 |
面色咣白 | 面无光泽 | 面色苍白 | 面色萎黄 |
舌象 | 舌质淡暗或瘀点 | 瘀斑 | |
脉象 | 脉沉涩或沉细无力 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100711714A CN1297290C (zh) | 2005-05-23 | 2005-05-23 | 一种治疗冠心病心绞痛的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100711714A CN1297290C (zh) | 2005-05-23 | 2005-05-23 | 一种治疗冠心病心绞痛的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1686485A true CN1686485A (zh) | 2005-10-26 |
CN1297290C CN1297290C (zh) | 2007-01-31 |
Family
ID=35304527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100711714A Active CN1297290C (zh) | 2005-05-23 | 2005-05-23 | 一种治疗冠心病心绞痛的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1297290C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102228493A (zh) * | 2011-06-27 | 2011-11-02 | 北京大学第一医院 | 一种治疗冠心病的药物 |
CN106265953A (zh) * | 2016-09-26 | 2017-01-04 | 四川聚豪生物科技有限公司 | 一种用于治疗冠心病心绞痛的蜜丸剂药物及制备方法 |
CN108295040A (zh) * | 2017-11-21 | 2018-07-20 | 吉林敖东集团大连药业股份有限公司 | 愈心痛胶囊制备方法 |
CN115068523A (zh) * | 2022-07-08 | 2022-09-20 | 大连胜光药业集团股份有限公司 | 一种治疗冠心病心绞痛药物的新应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1182862C (zh) * | 2003-03-06 | 2005-01-05 | 凌沛学 | 一种治疗冠心病心绞痛的中药制剂及其制备方法 |
-
2005
- 2005-05-23 CN CNB2005100711714A patent/CN1297290C/zh active Active
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102228493A (zh) * | 2011-06-27 | 2011-11-02 | 北京大学第一医院 | 一种治疗冠心病的药物 |
CN106265953A (zh) * | 2016-09-26 | 2017-01-04 | 四川聚豪生物科技有限公司 | 一种用于治疗冠心病心绞痛的蜜丸剂药物及制备方法 |
CN108295040A (zh) * | 2017-11-21 | 2018-07-20 | 吉林敖东集团大连药业股份有限公司 | 愈心痛胶囊制备方法 |
CN115068523A (zh) * | 2022-07-08 | 2022-09-20 | 大连胜光药业集团股份有限公司 | 一种治疗冠心病心绞痛药物的新应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1297290C (zh) | 2007-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1545382A (zh) | 加工人参的方法和加工过的人参提取物的用途 | |
CN106606529A (zh) | 一种具有辅助降血糖功效的组合物及其制备方法和应用 | |
CN100337662C (zh) | 一种治疗高血脂症的药物组合物及其制备方法 | |
CN1297290C (zh) | 一种治疗冠心病心绞痛的药物组合物及其制备方法 | |
CN1239183C (zh) | 一种中药组合物及其制备方法 | |
CN1212134C (zh) | 一种治疗泌尿***感染和***炎的中药复方制剂 | |
CN1698878A (zh) | 一种补肾的药物组合物及其制备方法和新用途 | |
CN1245189C (zh) | 一种扶正固本、健脾益肾,宁心安神,活血化淤的组合物 | |
CN1203872C (zh) | 一种治疗慢性结肠炎的药物 | |
CN1723964A (zh) | 一种治疗咳喘、慢性支气管炎的药物 | |
CN1232267C (zh) | 用于治疗脑血管疾病的组合物及其制备方法和应用 | |
CN103550281A (zh) | 一种预防和治疗糖尿病及其并发症的药物组合物及其制剂 | |
CN1559495A (zh) | 鹿胎颗粒中药制剂及生产工艺 | |
CN1706435A (zh) | 一种治疗经前期紧张综合征的中药组合物及其制备方法 | |
CN1119107A (zh) | 一种治疗呼吸***疾病特别是哮喘病的药品及其制备方法 | |
CN1246008C (zh) | 治疗急慢性鼻炎的中药制剂及其生产方法 | |
CN1256143C (zh) | 抗病毒的中药复方制剂 | |
CN1733089A (zh) | 治疗糖尿病及并发症的药物及其制备方法 | |
CN1973872A (zh) | 滋阴补肾强身健脑的药物及制备方法 | |
CN1314418C (zh) | 一种清肺化痰止咳平喘的药物及其制备方法 | |
JP2023505620A (ja) | 漢方薬組成物及びその製造方法並びに使用 | |
US11957726B2 (en) | Pharmaceutical composition for controlling blood sugar | |
CN1211111C (zh) | 一种降血脂中药 | |
CN102204956B (zh) | 一种用于中风恢复期的中药组合物及其制备方法 | |
CN1207030C (zh) | 一种具有抗肿瘤、抗自由基损伤和调节免疫的天然生物反应调节剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Jilin Aodong Group Dalian Pharmaceutical Co.,Ltd. Assignor: Liu Desheng|Song Zhiguo Contract fulfillment period: 2008.9.1 to 2014.9.1 Contract record no.: 2008110000043 Denomination of invention: Pharmaceutical composition for treating angina pectoris and preparation method thereof Granted publication date: 20070131 License type: Exclusive license Record date: 20081008 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.9.1 TO 2014.9.1; CHANGE OF CONTRACT Name of requester: JILIN AODONG GROUP DALIAN PHARMACEUTICAL CO., LTD. Effective date: 20081008 |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Jilin Aodong Group Dalian Pharmaceutical Co.,Ltd. Assignor: Liu Desheng|Song Zhiguo Contract record no.: 2008110000043 Date of cancellation: 20130401 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: SONG ZHIGUO Effective date: 20130716 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20130716 Address after: 116043 No. 65-604, four street, Dalian, Liaoning Patentee after: Liu Desheng Address before: 116043 No. 65-604, four street, Dalian, Liaoning Patentee before: Liu Desheng Patentee before: Song Zhiguo |
|
ASS | Succession or assignment of patent right |
Owner name: DALIAN SHENGHONG BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: LIU DESHENG Effective date: 20150708 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150708 Address after: 116045 Dalian, Liaoning Province, Tieshan Road, Lushunkou District, No. 168 Patentee after: Dalian Hong Sheng Biotechnology Co.,Ltd. Address before: 116043 No. 65-604, four street, Dalian, Liaoning Patentee before: Liu Desheng |
|
TR01 | Transfer of patent right |
Effective date of registration: 20190505 Address after: 116043 No. 477 Lushun North Road, Lushunkou District, Dalian City, Liaoning Province Patentee after: Dalian Shenghong Pharmaceutical Group Co.,Ltd. Address before: 116045 No. 168 Chuangzhan Road, Tieshan Street, Lushunkou District, Dalian City, Liaoning Province Patentee before: Dalian Hong Sheng Biotechnology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210127 Address after: 1-35-1, No.8, f District, Xinghai Square, Shahekou District, Dalian City, Liaoning Province, 116023 Patentee after: Liu Desheng Address before: 116043 No. 477 Lushun North Road, Lushunkou District, Dalian City, Liaoning Province Patentee before: Dalian Shenghong Pharmaceutical Group Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210318 Address after: No. 477, Lushun North Road (Sanjian section 4), Lushunkou District, Dalian, Liaoning, 116043 Patentee after: Dalian Shengguang Pharmaceutical Group Co.,Ltd. Address before: 1-35-1, No.8, f District, Xinghai Square, Shahekou District, Dalian City, Liaoning Province, 116023 Patentee before: Liu Desheng |
|
TR01 | Transfer of patent right | ||
CP02 | Change in the address of a patent holder |
Address after: 116043, Lushun North Road (three Jian section), Lushunkou District, Liaoning, Dalian, 477 Patentee after: Dalian Shengguang Pharmaceutical Group Co.,Ltd. Address before: No. 477, Lushun North Road (Sanjian section 4), Lushunkou District, Dalian, Liaoning, 116043 Patentee before: Dalian Shengguang Pharmaceutical Group Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A pharmaceutical composition for treating coronary heart disease and angina pectoris and its preparation method Effective date of registration: 20230908 Granted publication date: 20070131 Pledgee: China CITIC Bank Co.,Ltd. Dalian Branch Pledgor: Dalian Shengguang Pharmaceutical Group Co.,Ltd. Registration number: Y2023980056087 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |